EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles

Runze Wang iD, Hubert Th Wolterbeek, Antonia G Denkova

Journal of Labelled Compounds and Radiopharmaceuticals · 2024

DOI: 10.1002/jlcr.4121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Runze Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Delft, T…. Hauptthemen laut MEDLINE: Bismuth, Tellurium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radionuclide therapy employing alpha emitters holds great potential for personalized cancer treatment. However, certain challenges remain when designing alpha radiopharmaceuticals, including the lack of stability of used radioconjugates due to nuclear decay events. In this work, ultrasmall silver telluride nanoparticles with a core diameter of 2.1 nm were prepared and radiolabeled with lead‐212 using a chelator‐free method with a radiolabeling efficiency of 75%. The results from the in vitro radiochemical stability assay indicated a very high retention of bismuth‐212 despite the internal conversion effects originating from the decay of 212 Pb. To further evaluate the potential of the nanoparticles, they were radiolabeled with indium‐111, and their cell uptake and subcellular distribution were determined in 2D U87 cells, showing accumulation in the nucleus. Although not intentional, it was observed that the indium‐111‐radiolabeled nanoparticles induced efficient tumor cell killing, which was attributed to the Auger electrons emitted by indium‐111. Combining the results obtained in this work with other favorable properties such as fast renal clearance and the possibility to attach targeting vectors on the surface of the nanoparticles, all well‐known from the literature, these ultra‐small silver telluride nanoparticles provide exciting opportunities for the design of theragnostic radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BismuthTelluriumCell Line, TumorHumansSilverNanoparticlesLead RadioisotopesMetal NanoparticlesRadiopharmaceuticalsAnimalsIndium Radioisotopes

Stichwörter der Autor:innen

Auger electronsindium‐111internal conversionlead‐212/bismuth‐212 in vivo generatorradionuclide therapysilver telluride nanoparticle

Substanzen

BismuthTelluriumSilverLead RadioisotopesRadiopharmaceuticalsIndium-111Indium Radioisotopes

Autor:innen und Institutionen

  • Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Delft, The Netherlands.

ORCID-Profile: Runze Wang

Zitieren

APA

Wang, R., Wolterbeek, H. T., & Denkova, A. G. (2024). Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4121

Vancouver

Wang R, Wolterbeek HT, Denkova AG. Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4121

BibTeX
@article{Wang2024,
  author = {Wang, Runze and Wolterbeek, Hubert Th and Denkova, Antonia G},
  title = {Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2024},
  doi = {10.1002/jlcr.4121}
}
Kostenlos starten →